NEURON BIO

Trading sesion


06/12/2016 Close

1.0900

Last price


13.92 mill. €

Capitalisation

-0.91

Dif.(%)


-19.12

% Year 2016

Last Trade

Last

1.0900

Ref.

1.1000

Dif.(%)

-0.91

Volume (Shares)

4,600

Turnover (€x1000)

5.07

Security

Security name

NEURON BIO

Ticker

NEU

ISIN

ES0166198012

NIF

A-18758300

Capital Admitted

12.654.811,00 Euros

Shares Admitted

12.654.811

Nominal

1 Euros

Trading

Continuo

Liquidity Provider

GVC GAESCO BEKA, S.V., S.A.

Registered Advisor

GVC GAESCO BEKA, S.V., S.A.

Auditor

DELOITTE, S.L

Address

CL/ AVICENA 4, 18016 GRANADA

Contact

accionistas@neuronbio.com

Historical Summary

 20122013201420152016 until 5/12

Capital Admitted (thousands of euros)

4,6254,6256,9388,32512,655

Shares (x 1,000)

4,6254,6256,9388,32512,655

Period Close Price (euros)

2.40001.55002.30001.36001.1000

Period Last Price (euros)

2.35001.55002.30001.36001.1000

Period High Price (euros)

4.00002.40004.16003.28001.7800

Period Low Price (euros)

1.99001.09000.64001.29000.8900

Capitalisation (thousands of euros)

11,1007,16915,95611,32213,920

Volume (thousands of shares)

3671,00818,48615,04615,698

Turnover (thousands of euros)

1,1471,72241,44934,62118,781

Company Profile

Neuron Bio develops and manages biosolutions and projects in the biotechnological field for their application in the pharmaceutical and oleochemical industry through its subsidiaries and its specialized areas. 

Its pharma division is mainlydevoted to the search of drugs for the prevention and treatment of neurodegenerative diseases, particularly for the Alzheimer’s disease. 

Its diagnostic division develops tools and biomarkers for the diagnosis of human diseases, principally for those of the Central Nervous System as in the case of the Alzheimer’s disease.

Its service division develops research projects as well as consultancy services for public institutions and for companies of the pharmaceutical, biotechnological, agro-food and animal health area. 

Neuron Bio owns a broad and diverse high value molecule collection, neuroprotective compounds, 9 patent applications (1 of them granted recently by the US Patent and Trademark Office and other 2 also recently granted by the European Union) and exclusive platforms for drug discovery and development. 

Neol Bio, a subsidiary of Neuron Bio is devoted to the development of innovative processes within the microbial industrial biotechnology for its application in oleochemical, bioenergy and biopolymer sectors.

Due to the use of advanced molecular biology techniques, bioprocess engineering and industrial microbiology, Neol achieves economically viable bioprocesses, thus reducing the use of chemical contaminates and assessing agricultural and industrial waste. 

Neuron and Neol have facilities, laboratories and cutting-edge equipment in the biotechnology field, clean rooms, rodent and zebrafish facilities, including an own pilot plant for demonstration of the developed processes. 

They have a highly qualified team of researchers with wide experience in R&D and renowned prestige in the sector, who participate actively in numerous scientific projects, in which the company has already invested over €30 million. 

Neuron Bio has facilities in Granada and Madrid that are connected with university research centers and it is quoted on the Alternative Stock Market (MAB) in Spain.

Relevant Facts and Notices

Financial Reports

Photo Gallery

To obtain detailed information or information in other formats, please contact BME Market Data at marketdata@grupobme.es or visit the website www.bmemarketdata.es.

The information provided by the different websites of Grupo BME is for internal use only. For any commercial use and/or other usage that involves the redistribution of the information to third parties, it is required a prior and express permission from BME Market Data. Please contact us at marketdata@grupobme.es.

Copyright © Bolsas y Mercados Españoles 2016. All rights reserved. Disclaimer // Legal Disclaimer // Suppliers payment period